Warfarin pharmacogenetics: Challenges and opportunities for clinical translation

Frontiers in Pharmacology

Volumn 3 OCT, Issue , 2012, Pages

  Limdi, Nita A ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CYTOCHROME P450 2C9 GENE; DRUG EFFECT; DRUG SAFETY; GENE; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENETICS; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1 GENE;

EID: 84870767320     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00183     Document Type: Article

References (46)

1. Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., and Palareti, G. (2012). Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), e44S-e88S.
2. Aithal, G. P., Day, C. P., Kesteven, P. J. L., and Daly, A. K. (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719.
3. Altman, R., and Vidal, H. O. (2011). Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb. J. 9, 12.
4. Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., et al. (2007). Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570.
5. Anderson, J. L., Horne, B. D., Stevens, S. M., Woller, S. C., Samuelson, K. M., Mansfield, J. W., et al. (2012). A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (coumagen-II). Circulation 125, 1997-2005.
6. Ansell, J., Hollowell, J., Pengo, V., Martinez-Brotons, F., Caro, J., and Drouet, L. (2007). Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J. Thromb. Thrombolysis 23, 83-91.
7. Budnitz, D. S., Lovegrove, M. C., Shehab, N., and Richards, C. L. (2011). Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365, 2002-2012.
8. Budnitz, D. S., Shehab, N., Kegler, S. R., and Richards, C. L. (2007). Medication use leading to emergency department visits for adverse drug events in older adults. Ann. Intern. Med. 147, 755-765.
9. Cabral, K. P., Ansell, J., and Hylek, E. M. (2011). Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J. Thromb. Haemost. 9, 441-449.
10. Cardiology, ACo. (2012). Registry Data Shows Early Patterns for New Atrial Fibrillation Treatments. Available at: http://www.theheart.org/article/1435651. do [accessed: August 27, 2012].
11. Cavallari, L. H., Langaee, T. Y., Momary, K. M., Shapiro, N. L., Nutescu, E. A., Coty, W. A., et al. (2010). Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87, 459-464.
12. Cavallari, L. H., and Limdi, N. A. (2009). Warfarin pharmacogenomics. Curr. Opin. Mol. Ther. 11, 243-251.
13. Cavallari, L. H., and Perera, M. A. (2012). The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol. 8, 563-576.
14. Cha, P. C., Mushiroda, T., Takahashi, A., Kubo, M., Minami, S., Kamatani, N., et al. (2010). Genomewide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19, 4735-4744.
15. Chamberlain, M. A., Sageser, N. A., and Ruiz, D. (2001). Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. J. Am. Board Fam. Pract. 14, 16-21.
16. Chiquette, E., Amato, M. G., and Bussey, H. I. (1998). Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch. Intern. Med. 158, 1641-1647.
17. Cooper, G. M., Johnson, J. A., Langaee, T. Y., Gage, B. F., Scott, S. A., Stein, C. M., et al. (2008). A genomewide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027.
18. Finkelman, B. S., Gage, B. F., Johnson, J. A., Brensinger, C. M., and Kimmel, S. E. (2011). Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57, 612-618.
19. Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M., et al. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331.
20. Higashi, M. K., Veenstra, D. L., Kondo, L. M., Wittkowsky, A. K., Srinouanprachanh, S. L., Farin, F. M., et al. (2002). Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 3287, 1690-1698.
21. Hylek, E. M. (2003). Complications of oral anticoagulant therapy: bleeding and non bleeding, rates and risk factors. Semin. Vasc. Med. 3, 271-278.
22. Hylek, E. M., Chang, Y. C., Skates, S. J., Hughes, R. A., and Singer, D. E. (2000). Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch. Intern. Med. 160, 1612-1617.
23. Hylek, E. M., and Rose, A. J. (2009). Understanding low INR in clinical practice. Thromb. Haemost. 101, 417-418.
24. Hylek, E. M., and Singer, D. E. (1994). Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann. Intern. Med. 120, 897-902.
25. Hylek, E. M., Skates, S. J., Sheehan, M. A., and Singer, D. E. (1996). An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 335, 540-546.
26. Johnson, J. A. (2012). Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation 125, 1964-1966.
27. Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., et al. (2011). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629.
28. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T., et al. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764.
29. Limdi, N. A., McGwin, G., Goldstein, J. A., Beasley, T. M., Arnett, D. K., Adler, B. K., et al. (2008). Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321.
30. Limdi, N. A., and Veenstra, D. L. (2008). Warfarin pharmacogenetics. Pharmacotherapy 28, 1084-1097.
31. Limdi, N. A., and Veenstra, D. L. (2010). Expectations, validity, and reality in pharmacogenetics. J. Clin. Epidemiol. 63, 960-969.
32. Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. T., et al. (2010). Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827-3834.
33. Margaglione, M., Colaizzo, D., D'Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E., et al. (2000). Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84, 775-778.
34. Melnikova, I. (2009). The anticoagulants market. Nat. Rev. Drug Discov. 8, 353-354.
35. Perera, M., Limdi, N. A., Cavallari, L., Gamazon, E. R., Konkashbaev, A., Pluzhnikov, A., et al. (2011). Abstract 15518: novel SNPs associated with warfarin dose in a large multicenter cohort of African Americans: genome wide association study and replication results. Circulation 124, A15518.
36. Pradaxa, E. B. (dabigatran etexilate mesylate) U.S. (2012). Label Now Affirms Superior Reduction in Ischemic and Hemorrhagic Stroke Versus Warfarin in Patients with Non-Valvular Atrial Fibrillation. Available at: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2012/june_6_2012.html [accessed June 26, 2012].
37. Schirmer, S. H., Baumhakel, M., Neuberger, H. R., Hohnloser, S. H., van Gelder, I. C., Lip, G. Y., et al. (2010). Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J. Am. Coll. Cardiol. 56, 2067-2076.
38. Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., et al. (2009). A genomewide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433. doi: 10.1371/ journal.pgen.1000433
39. Tzeis, S., and Andrikopoulos, G. (2012). Novel anticoagulants for atrial fibrillation: a critical appraisal. Angiology 63, 164-170.
40. U.S.Census Bureau. (2010). The 2010 Statistical Abstract. Health and Nutrition: Health Care Utilization. Available at: http://www.census.gov/compendia/statab/cats/health_nutrition/health_care_utilization.html [accessed October 11, 2010].
41. Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., et al. (2007). Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34.
42. Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J., Bumpstead, S., et al. (2009). The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792.
43. Weitz, J. I., Eikelboom, J. W., and Samama, M. M. (2012). New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), e120S-e151S.
44. Wittkowsky, A. K. (2004). Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am. J. Manag. Care 10(Suppl. 10), S297-S306; discussion S312-S297.
45. Wittkowsky, A. K. (2011). Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy 31, 1175-1191.
46. Wittkowsky, A. K., and Devine, E. B. (2004). Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 24, 1311-1316.